{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:47:04Z","timestamp":1790380024474,"version":"4.1.0"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The appropriate use of systemic antifungals is vital in the prevention and treatment of invasive fungal infection (IFI) in immunosuppressed children and neonates. This multicenter observational study describes the inpatient prescribing practice of antifungal drugs for children and neonates and identifies factors associated with prescribing variability. A single-day point prevalence study of antimicrobial use in hospitalized neonates and children was performed between October and December 2012. The data were entered through a study-specific Web-based portal using a standardized data entry protocol. Data were recorded from 17,693 patients from 226 centers. A total of 136 centers recorded data from 1,092 children and 380 neonates receiving at least one antifungal agent. The most frequently prescribed systemic antifungals were fluconazole (\n            <jats:italic>n<\/jats:italic>\n            = 355) and amphotericin B deoxycholate (\n            <jats:italic>n<\/jats:italic>\n            = 195). The most common indications for antifungal administration in children were medical prophylaxis (\n            <jats:italic>n<\/jats:italic>\n            = 325), empirical treatment of febrile neutropenia (\n            <jats:italic>n<\/jats:italic>\n            = 122), and treatment of confirmed or suspected IFI (\n            <jats:italic>n<\/jats:italic>\n            = 100 [14%]). The treatment of suspected IFI in low-birthweight neonates accounted for the majority of prescriptions in the neonatal units (\n            <jats:italic>n<\/jats:italic>\n            = 103). An analysis of variance (ANOVA) demonstrated no significant effect of clinical indication (prophylaxis or treatment of systemic or localized infection) on the total daily dose (TDD). Fewer than one-half of the patients (\n            <jats:italic>n<\/jats:italic>\n            = 371) received a TDD within the dosing range recommended in the current guidelines. Subtherapeutic doses were prescribed in 416 cases (47%). The predominance of fluconazole and high incidence of subtherapeutic doses in participating hospitals may contribute to suboptimal clinical outcomes and an increased predominance of resistant pathogenic fungi. A global consensus on antifungal dosing and coordinated stewardship programs are needed to promote the consistent and appropriate use of antifungal drugs in neonates and children.\n          <\/jats:p>","DOI":"10.1128\/aac.04109-14","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T05:07:10Z","timestamp":1416287230000},"page":"782-789","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":50,"title":["Systemic Antifungal Prescribing in Neonates and Children: Outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study"],"prefix":"10.1128","volume":"59","author":[{"given":"J. M.","family":"Lestner","sequence":"first","affiliation":[{"name":"Pediatric Infectious Diseases Unit, St. George's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Versporten","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Microbiology, Vaccine &amp; Infectious Disease Institute, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Doerholt","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Unit, St. George's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Warris","sequence":"additional","affiliation":[{"name":"Institute of Medical Sciences, Aberdeen Fungal Group, University of Aberdeen, Aberdeen, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Roilides","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Salonica, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sharland","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Unit, St. George's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bielicki","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Unit, St. George's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Goossens","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Microbiology, Vaccine &amp; Infectious Disease Institute, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.09.011"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/513196"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-2-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/651263"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318286c612"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq430"},{"key":"e_1_3_2_8_2","volume-title":"British Association of Perinatal Medicine standards for hospitals providing neonatal intensive and high dependency care (second edition)","author":"BAPM","year":"2001","unstructured":"BAPM. 2001. British Association of Perinatal Medicine standards for hospitals providing neonatal intensive and high dependency care (second edition). British Association of Perinatal Medicine, London, United Kingdom. http:\/\/www.bapm.org\/publications\/documents\/guidelines\/hosp_standards.pdf."},{"key":"e_1_3_2_9_2","volume-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2014","unstructured":"R Development Core Team. 2014. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria."},{"key":"e_1_3_2_10_2","volume-title":"Stata statistical software: release 10","author":"Stata Corp","year":"2007","unstructured":"Stata Corp. 2007. Stata statistical software: release 10. StataCorp, College Station, TX."},{"key":"e_1_3_2_11_2","volume-title":"Anatomical Therapeutic Chemical (ATC) classification system: guidelines for ATC classification and DDD assignment","author":"WHO","year":"2013","unstructured":"WHO. 2013. Anatomical Therapeutic Chemical (ATC) classification system: guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway."},{"key":"e_1_3_2_12_2","volume-title":"Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings","author":"United Nations","year":"2011","unstructured":"United Nations. 2011. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. United Nations, New York, NY. http:\/\/unstats.un.org\/unsd\/methods\/m49\/m49regin.htm."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199573585.001.0001","volume-title":"Manual of childhood infections: the blue book","author":"Sharland M","year":"2011","unstructured":"Sharland M, Cant A, Davies EG, Elliman DAC, Esposito S, Finn A, Gray J, Heath PT, Lyall H, Pollard AJ, Ramsay ME, Riordan A, Shingadia D (ed). 2011. Manual of childhood infections: the blue book, 3rd ed. Oxford University Press, Oxford, United Kingdom.","edition":"3"},{"key":"e_1_3_2_14_2","volume-title":"Red book 2012: 2012 report of the Committee on Infectious Diseases","author":"Pickering LK","year":"2012","unstructured":"Pickering LK, Baker, Kimberlin DW, Long SS (ed). 2012. Red book 2012: 2012 report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, IL."},{"key":"e_1_3_2_15_2","volume-title":"Fluconazole 50mg capsules: summary of product characteristics","author":"Electronic Medicines Compendium","year":"2013","unstructured":"Electronic Medicines Compendium. 2013 Fluconazole 50mg capsules: summary of product characteristics. Electronic Medicines Compendium, Surrey, United Kingdom. http:\/\/www.medicines.org.uk\/emc\/medicine\/25882."},{"key":"e_1_3_2_16_2","volume-title":"(Voriconazole) Annex I: summary of product characteristics","author":"EMA","year":"2014","unstructured":"EMA. 2014. (Voriconazole) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002669\/WC500144015.pdf."},{"key":"e_1_3_2_17_2","volume-title":"(Caspofungin) Annex I: summary of product characteristics","author":"EMA","year":"2014","unstructured":"EMA. 2014. (Caspofungin) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000379\/WC500021033.pdf."},{"key":"e_1_3_2_18_2","volume-title":"(Itraconazole) Summary of product characteristics","author":"MHRA","year":"2013","unstructured":"MHRA. 2013. (Itraconazole) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1411711063531.pdf."},{"key":"e_1_3_2_19_2","volume-title":"(Posaconazole) Annex I: summary of product characteristics","author":"EMA","year":"2013","unstructured":"EMA. 2013. (Posaconazole) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000610\/WC500037784.pdf."},{"key":"e_1_3_2_20_2","volume-title":"(Fungizone) Summary of product characteristics","author":"MHRA","year":"2014","unstructured":"MHRA. 2014. (Fungizone) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1404458209656.pdf."},{"key":"e_1_3_2_21_2","volume-title":"(AmBisome) Summary of product characteristics","author":"MHRA","year":"2014","unstructured":"MHRA. 2014. (AmBisome) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1410502129659.pdf."},{"key":"e_1_3_2_22_2","volume-title":"(Abelcet) Summary of product characteristics","author":"MHRA","year":"2014","unstructured":"MHRA. 2014. (Abelcet) Summary of product characteristics. Medicines and Healthcare Products Regulatory Agency, London, United Kingdom."},{"key":"e_1_3_2_23_2","volume-title":"(Mycamine) Annex I: summary of product characteristics","author":"EMA","year":"2014","unstructured":"EMA. 2014. (Mycamine) Annex I: summary of product characteristics. European Medicines Agency, London, United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000734\/WC500031075.pdf."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.07.043"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12040"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70017-8"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp14X677842"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7551.1183"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.632-638.2006"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01679-09"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00751-08"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4536-4545.2005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.01.002"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000220256.69385.2e"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.08072.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3182737427"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819f1f50"},{"key":"e_1_3_2_38_2","volume-title":"AIDSinfo: guidelines for the use of antiretroviral agents in pediatric HIV infection","author":"U.S. Department of Health and Human Services","year":"2000","unstructured":"U.S. Department of Health and Human Services. 2000. AIDSinfo: guidelines for the use of antiretroviral agents in pediatric HIV infection. U.S. Department of Health and Human Services, Washington, DC. http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/pediatricguidelines.pdf"},{"key":"e_1_3_2_39_2","volume-title":"HIV\/AIDS Programme","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. 2010. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Recommendations for a public health approach, 2010 revision. HIV\/AIDS Programme, World Health Organization, Geneva, Switzerland. http:\/\/apps.who.int\/medicinedocs\/documents\/s18809en\/s18809en.pdf."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003543.pub3"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12622"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2013-000436.515"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2012.10.006"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku053"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.2241"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/591133"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2012-301728.4"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04109-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.04109-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:51:13Z","timestamp":1645483873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.04109-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1128\/AAC.04109-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.04109-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"2014-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}